View Future GrowthVitro. de 과거 순이익 실적과거 기준 점검 3/6Vitro. de은 연평균 45.5%의 비율로 수입이 증가해 온 반면, Packaging 산업은 수입이 6.7% 감소했습니다. 매출은 연평균 42%의 비율로 감소했습니다. Vitro. de의 자기자본이익률은 14.9%이고 순이익률은 46.7%입니다.핵심 정보45.52%순이익 성장률43.35%주당순이익(EPS) 성장률Packaging 산업 성장률9.45%매출 성장률-42.04%자기자본이익률14.92%순이익률46.69%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 06First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: US$17.0m (down 74% from 1Q 2025). Net income: US$6.00m (down 40% from 1Q 2025). Profit margin: 35% (up from 15% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 32% per year.분석 기사 • Nov 06We Like The Quality Of Vitro. de's (BMV:VITROA) EarningsVitro, S.A.B. de C.V.'s ( BMV:VITROA ) solid earnings announcement recently didn't do much to the stock price. We did...Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.072 (vs US$0.07 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.072 (up from US$0.07 loss in 3Q 2024). Revenue: US$72.0m (flat on 3Q 2024). Net income: US$34.0m (up US$68.5m from 3Q 2024). Profit margin: 47% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 32% per year.Reported Earnings • Jul 29Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: US$69.0m (down 1.4% from 2Q 2024). Net income: US$54.0m (up US$107.0m from 2Q 2024). Profit margin: 78% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 02Full year 2024 earnings released: US$0.21 loss per share (vs US$0.26 profit in FY 2023)Full year 2024 results: US$0.21 loss per share (down from US$0.26 profit in FY 2023). Revenue: US$284.0m (down 8.6% from FY 2023). Net loss: US$97.0m (down 179% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: US$72.0m (down 89% from 3Q 2023). Net loss: US$34.0m (down 337% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesReported Earnings • May 06First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: US$17.0m (down 74% from 1Q 2025). Net income: US$6.00m (down 40% from 1Q 2025). Profit margin: 35% (up from 15% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 32% per year.공시 • Mar 13Vitro, S.A.B. de C.V., Annual General Meeting, Mar 27, 2026Vitro, S.A.B. de C.V., Annual General Meeting, Mar 27, 2026. Location: ricardo margain zozaya, no 400 valle del campestre neighborhood, nuevo leon, san pedro garza garcia MexicoBoard Change • Feb 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Independent Director Mario Laborin Gomez was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Nov 06We Like The Quality Of Vitro. de's (BMV:VITROA) EarningsVitro, S.A.B. de C.V.'s ( BMV:VITROA ) solid earnings announcement recently didn't do much to the stock price. We did...Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.072 (vs US$0.07 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.072 (up from US$0.07 loss in 3Q 2024). Revenue: US$72.0m (flat on 3Q 2024). Net income: US$34.0m (up US$68.5m from 3Q 2024). Profit margin: 47% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 32% per year.Reported Earnings • Jul 29Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: US$69.0m (down 1.4% from 2Q 2024). Net income: US$54.0m (up US$107.0m from 2Q 2024). Profit margin: 78% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change).Buy Or Sell Opportunity • May 05Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to Mex$6.65. The fair value is estimated to be Mex$8.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 66% over the last 3 years. Meanwhile, the company became loss making.New Risk • May 02New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.공시 • Apr 02Vitro, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025Vitro, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: ricardo margain zozaya, no 400 valle del campestre neighborhood, nuevo leon, san pedro garza garcia MexicoBuy Or Sell Opportunity • Mar 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 25% to Mex$6.68. The fair value is estimated to be Mex$8.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 62% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Mar 02Full year 2024 earnings released: US$0.21 loss per share (vs US$0.26 profit in FY 2023)Full year 2024 results: US$0.21 loss per share (down from US$0.26 profit in FY 2023). Revenue: US$284.0m (down 8.6% from FY 2023). Net loss: US$97.0m (down 179% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: US$72.0m (down 89% from 3Q 2023). Net loss: US$34.0m (down 337% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.2% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.0% average weekly change).Reported Earnings • Jul 27Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: US$70.0m (down 89% from 2Q 2023). Net loss: US$53.0m (down 247% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 29First quarter 2024 earnings released: EPS: US$0.053 (vs US$0.08 in 1Q 2023)First quarter 2024 results: EPS: US$0.053 (down from US$0.08 in 1Q 2023). Revenue: US$71.0m (down 88% from 1Q 2023). Net income: US$25.0m (down 31% from 1Q 2023). Profit margin: 35% (up from 6.0% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Mar 28New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 52% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks High level of debt (52% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.분석 기사 • Mar 13Vitro, S.A.B. de C.V. (BMV:VITROA) May Have Run Too Fast Too Soon With Recent 25% Price PlummetUnfortunately for some shareholders, the Vitro, S.A.B. de C.V. ( BMV:VITROA ) share price has dived 25% in the last...Reported Earnings • Feb 29Full year 2023 earnings released: EPS: US$0.04 (vs US$0.038 in FY 2022)Full year 2023 results: EPS: US$0.04 (up from US$0.038 in FY 2022). Revenue: US$79.0m (down 97% from FY 2022). Net income: US$19.0m (up 6.4% from FY 2022). Profit margin: 24% (up from 0.8% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.분석 기사 • Jan 24Not Many Are Piling Into Vitro, S.A.B. de C.V. (BMV:VITROA) Stock Yet As It Plummets 48%Vitro, S.A.B. de C.V. ( BMV:VITROA ) shares have had a horrible month, losing 48% after a relatively good period...Valuation Update With 7 Day Price Move • Jan 23Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Mex$13.06, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 8x in the Packaging industry in South America. Total returns to shareholders of 72% over the past three years.분석 기사 • Jan 03Vitro. de's (BMV:VITROA) Returns On Capital Not Reflecting Well On The BusinessIf we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? More often...New Risk • Dec 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 4.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (4.1% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks High level of debt (53% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 45%After last week's 45% share price gain to Mex$27.50, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 13x in the Packaging industry in South America. Total returns to shareholders of 2.2% over the past three years.Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.03 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.03 (up from US$0.03 loss in 3Q 2022). Revenue: US$626.0m (flat on 3Q 2022). Net income: US$14.0m (up US$29.8m from 3Q 2022). Profit margin: 2.2% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: US$0.077 (vs US$0.02 in 2Q 2022)Second quarter 2023 results: EPS: US$0.077 (up from US$0.02 in 2Q 2022). Revenue: US$622.0m (up 7.0% from 2Q 2022). Net income: US$36.0m (up 321% from 2Q 2022). Profit margin: 5.8% (up from 1.5% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 21Full year 2022 earnings released: EPS: US$0.038 (vs US$0.23 loss in FY 2021)Full year 2022 results: EPS: US$0.038 (up from US$0.23 loss in FY 2021). Revenue: US$2.35b (up 20% from FY 2021). Net income: US$17.9m (up US$124.5m from FY 2021). Profit margin: 0.8% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Board Change • Nov 17Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 12 highly experienced directors. 5 independent directors (7 non-independent directors). Independent Director Guillermo Aponte Ortiz Martinez was the last independent director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 29Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.011 loss in 3Q 2021)Third quarter 2022 results: US$0.034 loss per share (further deteriorated from US$0.011 loss in 3Q 2021). Revenue: US$623.0m (up 27% from 3Q 2021). Net loss: US$16.0m (loss widened 214% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.Reported Earnings • Jul 29Second quarter 2022 earnings released: EPS: US$0.019 (vs US$0.02 loss in 2Q 2021)Second quarter 2022 results: EPS: US$0.019 (up from US$0.02 loss in 2Q 2021). Revenue: US$581.0m (up 21% from 2Q 2021). Net income: US$9.00m (up US$17.0m from 2Q 2021). Profit margin: 1.5% (up from net loss in 2Q 2021). Over the next year, revenue is forecast to stay flat compared to a 11% growth forecast for the industry in Mexico. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.Reported Earnings • May 05First quarter 2022 earnings released: EPS: US$0.04 (vs US$0.001 loss in 1Q 2021)First quarter 2022 results: EPS: US$0.04 (up from US$0.001 loss in 1Q 2021). Revenue: US$552.4m (up 16% from 1Q 2021). Net income: US$19.0m (up US$19.3m from 1Q 2021). Profit margin: 3.4% (up from net loss in 1Q 2021). Over the next year, revenue is forecast to grow 2.9%, compared to a 12% growth forecast for the industry in Mexico. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.Price Target Changed • Apr 27Price target increased to Mex$80.00Up from Mex$50.25, the current price target is provided by 1 analyst. New target price is 214% above last closing price of Mex$25.48. Stock is down 3.6% over the past year. The company posted a net loss per share of US$0.23 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 12 highly experienced directors. 5 independent directors (7 non-independent directors). Independent Director Guillermo Aponte Ortiz Martinez was the last independent director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$1.96b (up 11% from FY 2020). Net loss: US$107.0m (loss widened 136% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.Price Target Changed • Sep 14Price target increased to Mex$65.00Up from Mex$50.25, the current price target is provided by 1 analyst. New target price is 147% above last closing price of Mex$26.30.Reported Earnings • Jul 30Second quarter 2021 earnings releasedThe company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$480.5m (up 61% from 2Q 2020). Net loss: US$7.98m (loss narrowed 87% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 26Full year 2020 earnings released: US$0.096 loss per share (vs US$0.14 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$1.77b (down 19% from FY 2019). Net loss: US$45.4m (down 171% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.공시 • Jan 19DHS Private Equity Trust (AXS) cancelled the acquisition of Vitro, S.A.B. de C.V. (BMV:VITRO A).DHS Private Equity Trust (AXS) agreed to acquire Vitro, S.A.B. de C.V. (BMV:VITRO A) for approximately $1.2 billion on January 11, 2021. Simpson Thatcher acted as a legal advisor and Deutsche Bank Securities Inc. acted as a financial advisor to DHS. Santander Bank acted as a financial advisor and Ortega & Sons LLP acted as a legal advisor to Vitro. DHS Private Equity Trust (AXS) cancelled the acquisition of Vitro, S.A.B. de C.V. (BMV:VITRO A) on January 17, 2021.공시 • Jan 12DHS Private Equity Trust (AXS) agreed to acquire Vitro, S.A.B. de C.V. (BMV:VITRO A) for approximately $1.2 billion.DHS Private Equity Trust (AXS) agreed to acquire Vitro, S.A.B. de C.V. (BMV:VITRO A) for approximately $1.2 billion on January 11, 2021. Simpson Thatcher acted as a legal advisor and Deutsche Bank Securities Inc. acted as a financial advisor to DHS. Santander Bank acted as a financial advisor and Ortega & Sons LLP acted as a legal advisor to Vitro.분석 기사 • Jan 11What Is The Ownership Structure Like For Vitro, S.A.B. de C.V. (BMV:VITROA)?Every investor in Vitro, S.A.B. de C.V. ( BMV:VITROA ) should be aware of the most powerful shareholder groups...분석 기사 • Dec 21How Much Did Vitro. de's(BMV:VITROA) Shareholders Earn From Share Price Movements Over The Last Three Years?While not a mind-blowing move, it is good to see that the Vitro, S.A.B. de C.V. ( BMV:VITROA ) share price has gained...Valuation Update With 7 Day Price Move • Nov 27Market bids up stock over the past weekAfter last week's 35% share price gain to US$33.14, the stock is trading at a trailing P/E ratio of 16x, up from the previous P/E ratio of 11.8x. This compares to an average P/E of 13x in the Packaging industry in South America. Total return to shareholders over the past three years is a loss of 49%.Is New 90 Day High Low • Nov 24New 90-day high: Mex$25.37The company is up 10.0% from its price of Mex$23.02 on 26 August 2020. The Mexican market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is flat over the same period.분석 기사 • Nov 18Are Vitro. de's (BMV:VITROA) Statutory Earnings A Good Guide To Its Underlying Profitability?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...Is New 90 Day High Low • Oct 31New 90-day high: Mex$25.15The company is up 8.0% from its price of Mex$23.26 on 31 July 2020. The Mexican market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Packaging industry, which is up 18% over the same period.Reported Earnings • Oct 31Third quarter earnings releasedOver the last 12 months the company has reported total profits of US$49.1m, down 62% from the prior year. Total revenue was US$1.78b over the last 12 months, down 20% from the prior year.공시 • Sep 25+ 1 more updateSolutia Inc. signed a definitive agreement to acquire the 51% stake it did not already own in Quimica M, S.A. de C.V. from Vitro SA de CV for approximately $20 million.Solutia Inc. (OTCBB: SOLUQ) signed a definitive agreement to acquire the remaining 51% stake in Quimica M, S.A. de C.V. from Vitro SA de CV for a reported consideration of approximately $20 million on November 28, 2005. In a related transaction, Solutia and certain affiliates of Vitro Plan will enter into agreements under which Solutia will supply Vitro Plan affiliates with 100% of their requirements for Saflex and Vanceva PVB interlayer products. The transaction is subject to approvals by the Bankruptcy Court, the Boards of Directors, the Mexican Competition Commission, and by governmental authorities in Mexico and the US. Quimica M had sales of $47 million in 2004. Thomas Christopher and Vamsi Bonthala of Kirkland & Ellis served as legal advisor to Solutia.매출 및 비용 세부 내역Vitro. de가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BMV:VITRO A 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26284133100031 Dec 2528213097030 Sep 2527964113030 Jun 25279-5113031 Mar 25279-113105031 Dec 24284-97117030 Sep 24292-43106030 Jun 24-77323-63031 Mar 2430688115031 Dec 23311123117030 Sep 23-1,273125-141030 Jun 232,44363458031 Mar 232,40235448031 Dec 222523394030 Sep 222,268-81422030 Jun 222,136-71401031 Mar 222,036-87388031 Dec 211,958-107376030 Sep 211,939-145371030 Jun 211,924-126355031 Mar 211,742-178326031 Dec 201,768-45292030 Sep 201,78049290030 Jun 201,85876310031 Mar 202,125174336031 Dec 192,18064371030 Sep 192,216130372030 Jun 192,235148360031 Mar 192,236119363031 Dec 182,238162374030 Sep 182,225176361030 Jun 182,208178373031 Mar 182,202214372031 Dec 172,075194351030 Sep 171,958208342030 Jun 171,634204282031 Mar 171,266199220031 Dec 16957175162030 Sep 16837145143030 Jun 1686534150031 Mar 16884-10154031 Dec 15820-70143030 Sep 15763-133157030 Jun 15754-951580양질의 수익: VITRO A는 고품질 수익을 보유하고 있습니다.이익 마진 증가: VITRO A는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VITRO A는 지난 5년 동안 흑자전환하며 연평균 45.5%의 수익 성장을 기록했습니다.성장 가속화: VITRO A는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: VITRO A는 지난해 흑자전환하여 지난 해 수익 성장률을 Packaging 업계(1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VITRO A의 자본 수익률(14.9%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/14 10:32종가2026/05/06 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vitro, S.A.B. de C.V.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Lilian Ochoa GuerraGBM Grupo Bursátil Mexicano, S.A. de C.V. Casa de BolsaMiguel Mayorga TenaGBM Grupo Bursátil Mexicano, S.A. de C.V. Casa de BolsaJacob SteinfeldJ.P. Morgan
Reported Earnings • May 06First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: US$17.0m (down 74% from 1Q 2025). Net income: US$6.00m (down 40% from 1Q 2025). Profit margin: 35% (up from 15% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 32% per year.
분석 기사 • Nov 06We Like The Quality Of Vitro. de's (BMV:VITROA) EarningsVitro, S.A.B. de C.V.'s ( BMV:VITROA ) solid earnings announcement recently didn't do much to the stock price. We did...
Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.072 (vs US$0.07 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.072 (up from US$0.07 loss in 3Q 2024). Revenue: US$72.0m (flat on 3Q 2024). Net income: US$34.0m (up US$68.5m from 3Q 2024). Profit margin: 47% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 32% per year.
Reported Earnings • Jul 29Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: US$69.0m (down 1.4% from 2Q 2024). Net income: US$54.0m (up US$107.0m from 2Q 2024). Profit margin: 78% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 02Full year 2024 earnings released: US$0.21 loss per share (vs US$0.26 profit in FY 2023)Full year 2024 results: US$0.21 loss per share (down from US$0.26 profit in FY 2023). Revenue: US$284.0m (down 8.6% from FY 2023). Net loss: US$97.0m (down 179% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: US$72.0m (down 89% from 3Q 2023). Net loss: US$34.0m (down 337% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: US$17.0m (down 74% from 1Q 2025). Net income: US$6.00m (down 40% from 1Q 2025). Profit margin: 35% (up from 15% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 32% per year.
공시 • Mar 13Vitro, S.A.B. de C.V., Annual General Meeting, Mar 27, 2026Vitro, S.A.B. de C.V., Annual General Meeting, Mar 27, 2026. Location: ricardo margain zozaya, no 400 valle del campestre neighborhood, nuevo leon, san pedro garza garcia Mexico
Board Change • Feb 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Independent Director Mario Laborin Gomez was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Nov 06We Like The Quality Of Vitro. de's (BMV:VITROA) EarningsVitro, S.A.B. de C.V.'s ( BMV:VITROA ) solid earnings announcement recently didn't do much to the stock price. We did...
Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.072 (vs US$0.07 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.072 (up from US$0.07 loss in 3Q 2024). Revenue: US$72.0m (flat on 3Q 2024). Net income: US$34.0m (up US$68.5m from 3Q 2024). Profit margin: 47% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 32% per year.
Reported Earnings • Jul 29Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: US$69.0m (down 1.4% from 2Q 2024). Net income: US$54.0m (up US$107.0m from 2Q 2024). Profit margin: 78% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change).
Buy Or Sell Opportunity • May 05Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to Mex$6.65. The fair value is estimated to be Mex$8.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 66% over the last 3 years. Meanwhile, the company became loss making.
New Risk • May 02New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
공시 • Apr 02Vitro, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025Vitro, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: ricardo margain zozaya, no 400 valle del campestre neighborhood, nuevo leon, san pedro garza garcia Mexico
Buy Or Sell Opportunity • Mar 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 25% to Mex$6.68. The fair value is estimated to be Mex$8.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 62% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Mar 02Full year 2024 earnings released: US$0.21 loss per share (vs US$0.26 profit in FY 2023)Full year 2024 results: US$0.21 loss per share (down from US$0.26 profit in FY 2023). Revenue: US$284.0m (down 8.6% from FY 2023). Net loss: US$97.0m (down 179% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: US$72.0m (down 89% from 3Q 2023). Net loss: US$34.0m (down 337% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.2% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.0% average weekly change).
Reported Earnings • Jul 27Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: US$70.0m (down 89% from 2Q 2023). Net loss: US$53.0m (down 247% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 29First quarter 2024 earnings released: EPS: US$0.053 (vs US$0.08 in 1Q 2023)First quarter 2024 results: EPS: US$0.053 (down from US$0.08 in 1Q 2023). Revenue: US$71.0m (down 88% from 1Q 2023). Net income: US$25.0m (down 31% from 1Q 2023). Profit margin: 35% (up from 6.0% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Mar 28New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 52% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks High level of debt (52% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
분석 기사 • Mar 13Vitro, S.A.B. de C.V. (BMV:VITROA) May Have Run Too Fast Too Soon With Recent 25% Price PlummetUnfortunately for some shareholders, the Vitro, S.A.B. de C.V. ( BMV:VITROA ) share price has dived 25% in the last...
Reported Earnings • Feb 29Full year 2023 earnings released: EPS: US$0.04 (vs US$0.038 in FY 2022)Full year 2023 results: EPS: US$0.04 (up from US$0.038 in FY 2022). Revenue: US$79.0m (down 97% from FY 2022). Net income: US$19.0m (up 6.4% from FY 2022). Profit margin: 24% (up from 0.8% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
분석 기사 • Jan 24Not Many Are Piling Into Vitro, S.A.B. de C.V. (BMV:VITROA) Stock Yet As It Plummets 48%Vitro, S.A.B. de C.V. ( BMV:VITROA ) shares have had a horrible month, losing 48% after a relatively good period...
Valuation Update With 7 Day Price Move • Jan 23Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Mex$13.06, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 8x in the Packaging industry in South America. Total returns to shareholders of 72% over the past three years.
분석 기사 • Jan 03Vitro. de's (BMV:VITROA) Returns On Capital Not Reflecting Well On The BusinessIf we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? More often...
New Risk • Dec 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 4.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (4.1% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks High level of debt (53% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 45%After last week's 45% share price gain to Mex$27.50, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 13x in the Packaging industry in South America. Total returns to shareholders of 2.2% over the past three years.
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.03 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.03 (up from US$0.03 loss in 3Q 2022). Revenue: US$626.0m (flat on 3Q 2022). Net income: US$14.0m (up US$29.8m from 3Q 2022). Profit margin: 2.2% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: US$0.077 (vs US$0.02 in 2Q 2022)Second quarter 2023 results: EPS: US$0.077 (up from US$0.02 in 2Q 2022). Revenue: US$622.0m (up 7.0% from 2Q 2022). Net income: US$36.0m (up 321% from 2Q 2022). Profit margin: 5.8% (up from 1.5% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 21Full year 2022 earnings released: EPS: US$0.038 (vs US$0.23 loss in FY 2021)Full year 2022 results: EPS: US$0.038 (up from US$0.23 loss in FY 2021). Revenue: US$2.35b (up 20% from FY 2021). Net income: US$17.9m (up US$124.5m from FY 2021). Profit margin: 0.8% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Board Change • Nov 17Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 12 highly experienced directors. 5 independent directors (7 non-independent directors). Independent Director Guillermo Aponte Ortiz Martinez was the last independent director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 29Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.011 loss in 3Q 2021)Third quarter 2022 results: US$0.034 loss per share (further deteriorated from US$0.011 loss in 3Q 2021). Revenue: US$623.0m (up 27% from 3Q 2021). Net loss: US$16.0m (loss widened 214% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jul 29Second quarter 2022 earnings released: EPS: US$0.019 (vs US$0.02 loss in 2Q 2021)Second quarter 2022 results: EPS: US$0.019 (up from US$0.02 loss in 2Q 2021). Revenue: US$581.0m (up 21% from 2Q 2021). Net income: US$9.00m (up US$17.0m from 2Q 2021). Profit margin: 1.5% (up from net loss in 2Q 2021). Over the next year, revenue is forecast to stay flat compared to a 11% growth forecast for the industry in Mexico. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 05First quarter 2022 earnings released: EPS: US$0.04 (vs US$0.001 loss in 1Q 2021)First quarter 2022 results: EPS: US$0.04 (up from US$0.001 loss in 1Q 2021). Revenue: US$552.4m (up 16% from 1Q 2021). Net income: US$19.0m (up US$19.3m from 1Q 2021). Profit margin: 3.4% (up from net loss in 1Q 2021). Over the next year, revenue is forecast to grow 2.9%, compared to a 12% growth forecast for the industry in Mexico. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
Price Target Changed • Apr 27Price target increased to Mex$80.00Up from Mex$50.25, the current price target is provided by 1 analyst. New target price is 214% above last closing price of Mex$25.48. Stock is down 3.6% over the past year. The company posted a net loss per share of US$0.23 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 12 highly experienced directors. 5 independent directors (7 non-independent directors). Independent Director Guillermo Aponte Ortiz Martinez was the last independent director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$1.96b (up 11% from FY 2020). Net loss: US$107.0m (loss widened 136% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
Price Target Changed • Sep 14Price target increased to Mex$65.00Up from Mex$50.25, the current price target is provided by 1 analyst. New target price is 147% above last closing price of Mex$26.30.
Reported Earnings • Jul 30Second quarter 2021 earnings releasedThe company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$480.5m (up 61% from 2Q 2020). Net loss: US$7.98m (loss narrowed 87% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 26Full year 2020 earnings released: US$0.096 loss per share (vs US$0.14 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$1.77b (down 19% from FY 2019). Net loss: US$45.4m (down 171% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
공시 • Jan 19DHS Private Equity Trust (AXS) cancelled the acquisition of Vitro, S.A.B. de C.V. (BMV:VITRO A).DHS Private Equity Trust (AXS) agreed to acquire Vitro, S.A.B. de C.V. (BMV:VITRO A) for approximately $1.2 billion on January 11, 2021. Simpson Thatcher acted as a legal advisor and Deutsche Bank Securities Inc. acted as a financial advisor to DHS. Santander Bank acted as a financial advisor and Ortega & Sons LLP acted as a legal advisor to Vitro. DHS Private Equity Trust (AXS) cancelled the acquisition of Vitro, S.A.B. de C.V. (BMV:VITRO A) on January 17, 2021.
공시 • Jan 12DHS Private Equity Trust (AXS) agreed to acquire Vitro, S.A.B. de C.V. (BMV:VITRO A) for approximately $1.2 billion.DHS Private Equity Trust (AXS) agreed to acquire Vitro, S.A.B. de C.V. (BMV:VITRO A) for approximately $1.2 billion on January 11, 2021. Simpson Thatcher acted as a legal advisor and Deutsche Bank Securities Inc. acted as a financial advisor to DHS. Santander Bank acted as a financial advisor and Ortega & Sons LLP acted as a legal advisor to Vitro.
분석 기사 • Jan 11What Is The Ownership Structure Like For Vitro, S.A.B. de C.V. (BMV:VITROA)?Every investor in Vitro, S.A.B. de C.V. ( BMV:VITROA ) should be aware of the most powerful shareholder groups...
분석 기사 • Dec 21How Much Did Vitro. de's(BMV:VITROA) Shareholders Earn From Share Price Movements Over The Last Three Years?While not a mind-blowing move, it is good to see that the Vitro, S.A.B. de C.V. ( BMV:VITROA ) share price has gained...
Valuation Update With 7 Day Price Move • Nov 27Market bids up stock over the past weekAfter last week's 35% share price gain to US$33.14, the stock is trading at a trailing P/E ratio of 16x, up from the previous P/E ratio of 11.8x. This compares to an average P/E of 13x in the Packaging industry in South America. Total return to shareholders over the past three years is a loss of 49%.
Is New 90 Day High Low • Nov 24New 90-day high: Mex$25.37The company is up 10.0% from its price of Mex$23.02 on 26 August 2020. The Mexican market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is flat over the same period.
분석 기사 • Nov 18Are Vitro. de's (BMV:VITROA) Statutory Earnings A Good Guide To Its Underlying Profitability?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Is New 90 Day High Low • Oct 31New 90-day high: Mex$25.15The company is up 8.0% from its price of Mex$23.26 on 31 July 2020. The Mexican market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Packaging industry, which is up 18% over the same period.
Reported Earnings • Oct 31Third quarter earnings releasedOver the last 12 months the company has reported total profits of US$49.1m, down 62% from the prior year. Total revenue was US$1.78b over the last 12 months, down 20% from the prior year.
공시 • Sep 25+ 1 more updateSolutia Inc. signed a definitive agreement to acquire the 51% stake it did not already own in Quimica M, S.A. de C.V. from Vitro SA de CV for approximately $20 million.Solutia Inc. (OTCBB: SOLUQ) signed a definitive agreement to acquire the remaining 51% stake in Quimica M, S.A. de C.V. from Vitro SA de CV for a reported consideration of approximately $20 million on November 28, 2005. In a related transaction, Solutia and certain affiliates of Vitro Plan will enter into agreements under which Solutia will supply Vitro Plan affiliates with 100% of their requirements for Saflex and Vanceva PVB interlayer products. The transaction is subject to approvals by the Bankruptcy Court, the Boards of Directors, the Mexican Competition Commission, and by governmental authorities in Mexico and the US. Quimica M had sales of $47 million in 2004. Thomas Christopher and Vamsi Bonthala of Kirkland & Ellis served as legal advisor to Solutia.